Wall Street analysts predict that Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) will announce $51.43 million in sales for the current quarter, according to Zacks Investment Research. Three analysts have issued estimates for Vanda Pharmaceuticals’ earnings. The highest sales estimate is $53.00 million and the lowest is $49.70 million. Vanda Pharmaceuticals reported sales of $44.28 million in the same quarter last year, which would suggest a positive year over year growth rate of 16.1%. The firm is expected to announce its next earnings report on Wednesday, February 13th.
On average, analysts expect that Vanda Pharmaceuticals will report full-year sales of $191.47 million for the current fiscal year, with estimates ranging from $189.70 million to $193.00 million. For the next year, analysts forecast that the business will post sales of $253.30 million, with estimates ranging from $229.00 million to $292.00 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side analysts that that provide coverage for Vanda Pharmaceuticals.
Vanda Pharmaceuticals (NASDAQ:VNDA) last issued its earnings results on Wednesday, November 7th. The biopharmaceutical company reported $0.13 earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.05) by $0.18. Vanda Pharmaceuticals had a return on equity of 5.88% and a net margin of 7.06%. The business had revenue of $49.13 million during the quarter, compared to analyst estimates of $49.44 million. During the same quarter in the previous year, the firm earned ($0.03) EPS. Vanda Pharmaceuticals’s revenue was up 18.9% on a year-over-year basis.
A number of equities research analysts have issued reports on VNDA shares. TheStreet upgraded Vanda Pharmaceuticals from a “c” rating to a “b-” rating in a research note on Friday, October 26th. Oppenheimer set a $29.00 price target on Vanda Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, October 3rd. Stifel Nicolaus started coverage on Vanda Pharmaceuticals in a research note on Thursday, September 13th. They set a “buy” rating and a $30.00 price target for the company. Citigroup boosted their price target on Vanda Pharmaceuticals from $27.00 to $31.00 and gave the company a “buy” rating in a research note on Tuesday, October 16th. Finally, Zacks Investment Research upgraded Vanda Pharmaceuticals from a “hold” rating to a “buy” rating and set a $26.00 price target for the company in a research note on Friday, October 12th. Eight research analysts have rated the stock with a buy rating and three have assigned a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $35.38.
NASDAQ:VNDA traded up $0.51 during mid-day trading on Monday, reaching $29.45. The company’s stock had a trading volume of 72,922 shares, compared to its average volume of 848,630. Vanda Pharmaceuticals has a 12-month low of $13.30 and a 12-month high of $33.44. The firm has a market cap of $1.52 billion, a price-to-earnings ratio of -84.06, a price-to-earnings-growth ratio of 3.94 and a beta of 0.87.
Institutional investors have recently added to or reduced their stakes in the business. United Services Automobile Association bought a new position in shares of Vanda Pharmaceuticals during the 3rd quarter valued at approximately $211,000. Trexquant Investment LP bought a new position in shares of Vanda Pharmaceuticals during the 2nd quarter valued at approximately $212,000. Hartford Investment Management Co. bought a new position in shares of Vanda Pharmaceuticals during the 2nd quarter valued at approximately $214,000. Meeder Asset Management Inc. grew its stake in shares of Vanda Pharmaceuticals by 164.6% during the 3rd quarter. Meeder Asset Management Inc. now owns 11,417 shares of the biopharmaceutical company’s stock valued at $261,000 after acquiring an additional 7,102 shares during the period. Finally, NumerixS Investment Technologies Inc grew its stake in shares of Vanda Pharmaceuticals by 92.9% during the 2nd quarter. NumerixS Investment Technologies Inc now owns 11,835 shares of the biopharmaceutical company’s stock valued at $227,000 after acquiring an additional 5,700 shares during the period. Institutional investors and hedge funds own 99.33% of the company’s stock.
About Vanda Pharmaceuticals
Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system disorders. The company's marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorders; and Fanapt (iloperidone), a product for the treatment of schizophrenia.
Further Reading: How is the LIBOR rate calculated?
Get a free copy of the Zacks research report on Vanda Pharmaceuticals (VNDA)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.